Were Hedge Funds Right About ASLAN Pharmaceuticals Limited (ASLN)?
Is ASLAN Pharmaceuticals Limited (NASDAQ:ASLN) a good place to invest some of your money right now? We can gain invaluable insight to help us answer that question by studying the investment trends of top investors, who employ world-class Ivy League graduates, who are given immense resources and industry contacts to put their financial expertise to work. The top picks of these firms have historically outperformed the market when we account for known risk factors, making them very valuable investment ideas.
ASLAN Pharmaceuticals Limited (NASDAQ:ASLN) has experienced an increase in hedge fund interest recently. ASLAN Pharmaceuticals Limited (NASDAQ:ASLN) was in 18 hedge funds’ portfolios at the end of March. The all time high for this statistic was previously 5. This means the bullish number of hedge fund positions in this stock currently sits at its all time high. There were 5 hedge funds in our database with ASLN p
Is Kinnate Biopharma Inc (KNTE) A Good Stock To Buy? insidermonkey.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from insidermonkey.com Daily Mail and Mail on Sunday newspapers.
Were Hedge Funds Right About Piling Into IGM Biosciences, Inc. (IGMS)?
The Insider Monkey team has completed processing the quarterly 13F filings for the March quarter submitted by the hedge funds and other money managers included in our extensive database. Most hedge fund investors experienced strong gains on the back of a strong market performance, which certainly propelled them to adjust their equity holdings so as to maintain the desired risk profile. As a result, the relevancy of these public filings and their content is indisputable, as they may reveal numerous high-potential stocks. The following article will discuss the smart money sentiment towards IGM Biosciences, Inc. (NASDAQ:IGMS).
Were Hedge Funds Right About Repare Therapeutics Inc. (RPTX)?
The financial regulations require hedge funds and wealthy investors that exceeded the $100 million holdings threshold to file a report that shows their positions at the end of every quarter. Even though it isn’t the intention, these filings to a certain extent level the playing field for ordinary investors. The latest round of 13F filings disclosed the funds’ positions on March 31st. We at Insider Monkey have made an extensive database of more than 866 of those established hedge funds and famous value investors’ filings. In this article, we analyze how these elite funds and prominent investors traded Repare Therapeutics Inc. (NASDAQ:RPTX) based on those filings.
socaltech.com
San Diego-based
Design Therapeutics, a biotech company which is developing small molecules for the treatment of serious degenerative disorders caused by inherited nucleotide repeat expansions, said it has raised $125M in its Series B funding round. The funding was led by Logos Cpaital, and also included Cormorant Asset Management, SR One, Quan Capital and WestRiver Group, plus funds and accounts managed by BlackRock, Janus Henderson Investors, RA Capital Management, Surveyor Capital (a Citadel company), funds and accounts advised by T. Rowe Price Associates, Inc., Wellington Management, Avoro Capital Advisors, Vivo Capital, and others. The company said the funding will go to advance its pipeline. Arsani William, M.D., managing partner and chief investment officer of Logos Capital, and John Schmid, industry veteran and former chief financial officer of Auspex Pharmaceuticals, have both joined the company s board with the funding.